WO2011038473A8 - Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos - Google Patents

Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos Download PDF

Info

Publication number
WO2011038473A8
WO2011038473A8 PCT/BR2010/000323 BR2010000323W WO2011038473A8 WO 2011038473 A8 WO2011038473 A8 WO 2011038473A8 BR 2010000323 W BR2010000323 W BR 2010000323W WO 2011038473 A8 WO2011038473 A8 WO 2011038473A8
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
virus
dna
inducing
basis
Prior art date
Application number
PCT/BR2010/000323
Other languages
English (en)
French (fr)
Other versions
WO2011038473A1 (pt
Inventor
Ada María de Barcelos ALVES
Adriana de Souza AZEVEDO
Ricardo Galller
Marcos Da Silva Freire
Original Assignee
Fundação Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43825448&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011038473(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundação Oswaldo Cruz filed Critical Fundação Oswaldo Cruz
Priority to US13/499,697 priority Critical patent/US10357558B2/en
Priority to CN201080052438.4A priority patent/CN102711817B/zh
Priority to EP10819756.7A priority patent/EP2484376A4/en
Publication of WO2011038473A1 publication Critical patent/WO2011038473A1/pt
Priority to CU20120057A priority patent/CU24060B1/es
Publication of WO2011038473A8 publication Critical patent/WO2011038473A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A presente invenção se refere a um método para induzir resposta imune contra vírus da dengue baseado em vacinas de DNA e vírus quiméricos 17D em imunizações combinadas ou coadministradas. Tambén estão dentro do escopo da presente invenção, vacinas de DNA contra os quatro sorotipos do vírus dengue a partir da construção de diferentes plasmídeos recombinantes contendo o gene que codifica a proteina E, ou somente a seqüência que corresponde ao dominio III desta proteína, a partir de cada sorotipo viral do virus dengue (DENV1-4). A invenção fornece ainda uma composição vacinal consistiendo de (a) vacinas de DNA contra os quatro sorotipos do virus dengue, (b) virus quiméricos compreendendo o virus vacinal de febre amarella 17D modificado; e (c) um veículo farmaceuticamente aceitável, está incluido no escopo de proteção.
PCT/BR2010/000323 2009-10-01 2010-08-01 Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos WO2011038473A1 (pt)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/499,697 US10357558B2 (en) 2009-10-01 2010-08-01 Method, kit, plasmid and composition for inducing an immune response to dengue virus, on the basis of DNA and chimeric virus vaccines
CN201080052438.4A CN102711817B (zh) 2009-10-01 2010-08-01 基于dna疫苗和嵌合体病毒的诱导抗登革热病毒的免疫应答的方法、试剂盒、质粒和组合物
EP10819756.7A EP2484376A4 (en) 2009-10-01 2010-08-01 METHOD, KIT, PLASMID AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE AGAINST THE DENGUE VIRUS USING DNA VACCINES AND CHIMERIC VIRUSES
CU20120057A CU24060B1 (es) 2009-10-01 2012-04-02 Composición vacunal contra el virus del dengue, kit y plásmido

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0904020A BRPI0904020B8 (pt) 2009-10-01 2009-10-01 composição vacinal contra o vírus da dengue, e, kit
BRPI0904020-0 2009-10-01

Publications (2)

Publication Number Publication Date
WO2011038473A1 WO2011038473A1 (pt) 2011-04-07
WO2011038473A8 true WO2011038473A8 (pt) 2012-07-19

Family

ID=43825448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2010/000323 WO2011038473A1 (pt) 2009-10-01 2010-08-01 Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos

Country Status (10)

Country Link
US (1) US10357558B2 (pt)
EP (1) EP2484376A4 (pt)
CN (1) CN102711817B (pt)
BR (1) BRPI0904020B8 (pt)
CL (1) CL2012000783A1 (pt)
CO (1) CO6541529A2 (pt)
CU (1) CU24060B1 (pt)
EC (1) ECSP12012131A (pt)
PE (2) PE20121171A1 (pt)
WO (1) WO2011038473A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539565T3 (pl) * 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
KR20160023683A (ko) 2013-06-21 2016-03-03 머크 샤프 앤드 돔 코포레이션 뎅기 바이러스 백신 조성물 및 그의 사용 방법
ITRM20130458A1 (it) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
WO2016106107A2 (en) * 2014-12-22 2016-06-30 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6881723B1 (en) * 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
NZ535690A (en) * 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
JP5227172B2 (ja) 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2086526B1 (en) * 2006-11-09 2014-07-23 The United States Of America As Represented By The Secretary of the Navy Induction of an immune response against Dengue virus using prime-boost approach
CN101909635B (zh) * 2008-01-11 2014-09-17 Vgx药品有限责任公司 针对多种登革病毒亚型的新颖疫苗

Also Published As

Publication number Publication date
PE20161094A1 (es) 2016-10-22
US20120251570A1 (en) 2012-10-04
WO2011038473A1 (pt) 2011-04-07
CO6541529A2 (es) 2012-10-16
EP2484376A4 (en) 2014-01-22
CN102711817A (zh) 2012-10-03
PE20121171A1 (es) 2012-08-30
CU20120057A7 (es) 2013-01-30
CL2012000783A1 (es) 2013-03-22
CN102711817B (zh) 2016-10-26
EP2484376A1 (en) 2012-08-08
CU24060B1 (es) 2014-12-26
US10357558B2 (en) 2019-07-23
BRPI0904020B1 (pt) 2019-11-12
ECSP12012131A (es) 2013-02-28
BRPI0904020A2 (pt) 2011-06-14
BRPI0904020B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
WO2008115199A3 (en) Chimeric virus vaccines
ZA200701176B (en) Vaccines against aids comprising CMV/R-nucleic acid constructs
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
WO2016034678A3 (en) Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
WO2010057159A3 (en) Antigens that elicit immune response against flavivirus and methods of using same
WO2003072719A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
WO2008121992A3 (en) Attenuated viruses useful for vaccines
WO2008014521A3 (en) Improved vaccines and methods for using the same
WO2013082317A8 (en) Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
WO2010115133A8 (en) Newcastle disease virus vectored avian vaccines
WO2010019262A3 (en) Polyvalent vaccine
IN2012DN03928A (pt)
WO2004096993A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2011153351A3 (en) Novel modified live-attenuated vaccines (mlv) and subunit vaccines created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv)
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
JP2017526689A5 (pt)
AR071910A1 (es) Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
WO2016116905A9 (en) Cmv antigens and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080052438.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10819756

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012000783

Country of ref document: CL

Ref document number: 000411-2012

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 927/MUMNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010819756

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12069004

Country of ref document: CO

Ref document number: 14237334

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 13499697

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 001214-2016

Country of ref document: PE